PT - JOURNAL ARTICLE AU - Sahin, Ugur AU - Muik, Alexander AU - Vogler, Isabel AU - Derhovanessian, Evelyna AU - Kranz, Lena M. AU - Vormehr, Mathias AU - Quandt, Jasmin AU - Bidmon, Nicole AU - Ulges, Alexander AU - Baum, Alina AU - Pascal, Kristen AU - Maurus, Daniel AU - Brachtendorf, Sebastian AU - Lörks, Verena AU - Sikorski, Julian AU - Koch, Peter AU - Hilker, Rolf AU - Becker, Dirk AU - Eller, Ann-Kathrin AU - Grützner, Jan AU - Tonigold, Manuel AU - Boesler, Carsten AU - Rosenbaum, Corinna AU - Heesen, Ludwig AU - Kühnle, Marie-Cristine AU - Poran, Asaf AU - Dong, Jesse Z. AU - Luxemburger, Ulrich AU - Kemmer-Brück, Alexandra AU - Langer, David AU - Bexon, Martin AU - Bolte, Stefanie AU - Palanche, Tania AU - Schultz, Armin AU - Baumann, Sybille AU - Mahiny, Azita J. AU - Boros, Gábor AU - Reinholz, Jonas AU - Szabó, Gábor T. AU - Karikó, Katalin AU - Shi, Pei-Yong AU - Fontes-Garfias, Camila AU - Perez, John L. AU - Cutler, Mark AU - Cooper, David AU - Kyratsous, Christos A. AU - Dormitzer, Philip R. AU - Jansen, Kathrin U. AU - Türeci, Özlem TI - BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans AID - 10.1101/2020.12.09.20245175 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.09.20245175 4099 - http://medrxiv.org/content/early/2020/12/11/2020.12.09.20245175.short 4100 - http://medrxiv.org/content/early/2020/12/11/2020.12.09.20245175.full AB - BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy to prevent coronavirus disease 2019 (COVID-19). Recently, we reported preliminary BNT162b2 safety and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 vaccine trial1. We present here antibody and T cell responses from a second, non-randomized open-label phase 1/2 trial in healthy adults, 19-55 years of age, after BNT162b2 prime/boost vaccination at 1 to 30 µg dose levels. BNT162b2 elicited strong antibody responses, with S-binding IgG concentrations above those in a COVID-19 human convalescent sample (HCS) panel. Day 29 (7 days post-boost) SARS-CoV-2 serum 50% neutralising geometric mean titers were 0.3-fold (1 µg) to 3.3-fold (30 µg) those of the HCS panel. The BNT162b2-elicited sera neutralised pseudoviruses with diverse SARS-CoV-2 S variants. Concurrently, in most participants, S-specific CD8+ and T helper type 1 (TH1) CD4+ T cells had expanded, with a high fraction producing interferon-γ (IFNγ). Using peptide MHC multimers, the epitopes recognised by several BNT162b2-induced CD8+ T cells when presented on frequent MHC alleles were identified. CD8+ T cells were shown to be of the early-differentiated effector-memory phenotype, with single specificities reaching 0.01-3% of circulating CD8+ T cells. In summary, vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19.Competing Interest StatementThe authors declare: U.S. and O.T. are management board members and employees at BioNTech SE (Mainz, Germany); A. K.-B., A.-K.E., A.U., C.R., D.B., P.K., D.L., D.M., E.D., J.G., J. S., M.-C.K., R.H., S. Bolte, S. Brachtendorf, T.P., U.L. and V.L. are employees at BioNTech SE; A.J.M., A.M., G.B., G.T.S., I.V., J.R., J.Q., K.K., L.M.K., N.B., and M.V. are employees at BioNTech RNA Pharmaceuticals GmbH; A.P. and J.Z.D are employees at BioNTech US; M.B. is an employee at Bexon Clinical Consulting LLC. A.B., C.A.K. and K.P. are employees of Regeneron Pharmaceuticals Inc; A.M., K.K., O.T. and U.S. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine; A.K.-B., J.Z.D., A.J.M., A.M., C.R., G.B., D.B., D.L., E.D., I.V., J.G., K.K., L.M.K., A.P., M.V., N.B., O.T., R.H., S. Bolte, U.L. and U.S. have securities from BioNTech SE; D.C., M.C., P.R.D., K.U.J. and J.L.P. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to perform the neutralisation assay; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT04380701Funding StatementBioNTech is the Sponsor of the study and responsible for the design, data collection, data analysis, data interpretation, and writing of the report. Pfizer advised on the study and the manuscript, generated serological data, and contracted for the generation of serological data. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit the data for publication. All study data were available to all authors. This study was not supported by any external funding at the time of submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was carried out in Germany in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an independent ethics committee (Ethik-Kommission of the Landesaerztekammer Baden-Wuerttemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich Institute, Langen, Germany).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. Upon completion of this clinical trial, summary-level results will be made public and shared in line with data sharing guidelines.